Skip to content

Pentazocine

    Brands

    DEA Class; Rx

    Common Brand Names; Talwin

    • Mixed Opiate Agonist-Antagonist

    Synthetic opiate agonist-antagonist analgesic
    One-sixth to one-third as potent as morphine
    Less incidence of adverse reactions than with morphine and other opiates

    Indicated for the treatment of moderate pain to severe pain.

    For preanesthesia medication, as well as adjunctive use in general anesthesia induction and general anesthesia maintenance.

    —

    seizures 
    increased intracranial pressure 
    toxic epidermal necrolysis 
    angioedema 
    Stevens-Johnson syndrome
    erythema multiforme 
    anaphylactic shock 
    apnea 
    neonatal opioid withdrawal syndrome 
    serotonin syndrome 
    SIADH 

    —

    Pentazocine has been detected in human milk. Consider the developmental and health benefits of breast-feeding along with the mother’s clinical need for pentazocine and any potential adverse effects on the breast-fed infant from pentazocine or the underlying maternal condition.

    Adults

    360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.

    Geriatric

    360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.

    Adolescents

    17 years: 360 mg/day IV/IM/SQ, not to exceed 30 mg/dose IV or 60 mg/dose IM/SQ.
    < 17 years: 0.5 mg/kg IM (up to 30 mg) x1 dose.

    Children

    0.5 mg/kg IM (up to 30 mg) x1 dose.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Pentazocine

    Talwin Intramuscular Inj Sol: 1mL, 30mg
    Talwin Intravenous Inj Sol: 1mL, 30mg
    Talwin Subcutaneous Inj Sol: 1mL, 30mg